Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

Santhera Pharmaceuticals Holding AG (SPHDF)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
1.41000.0000 (0.00%)
At close: 03:28PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close1.4100
Open1.4100
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range1.4100 - 1.4100
52 Week Range1.3700 - 3.7600
Volume500
Avg. Volume0
Market Cap27.857M
Beta (5Y Monthly)1.05
PE Ratio (TTM)N/A
EPS (TTM)-3.2790
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Santhera will Publish its 2021 Annual Report by June 3, 2022, and Hold its Annual General Meeting on June 29, 2022

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, April 29, 2022 -- Santhera Pharmaceuticals (SIX: SANN) will publish its annual report for the year 2021 by June 3, 2022 and hold its Annual General Meeting on June 29, 2022. Santhera will publish its annual report for the financial year 2021 by June 3, 2022, as permitted by SIX Exchange Regulation, in order to enable Santhera to reflect developments that could include progress with its ongoing financing activities. Santhera has sc

  • GlobeNewswire

    Santhera Appoints Shabir Hasham as Chief Medical Officer and Member of the Executive Management Team

    Ad hoc announcement pursuant to Art. 53 LR Pratteln, Switzerland, April 13, 2022 – Santhera Pharmaceuticals (SIX: SANN) announces the appointment of Shabir Hasham, MD, as Chief Medical Officer (CMO) and a member of Santhera’s Executive Management team, effective May 1, 2022. Shabir has served as Santhera’s Global Development Program Lead & Global Head Medical Affairs for the past three years. In this role, Shabir was primarily responsible for overseeing the clinical development and regulatory su

  • GlobeNewswire

    Santhera and ReveraGen Start Rolling NDA Submission to the FDA for Vamorolone for the Treatment of Duchenne Muscular Dystrophy

    Pratteln, Switzerland, March 29, 2022 – Santhera Pharmaceuticals (SIX: SANN) and ReveraGen BioPharma, Inc (US: private) announce the initiation of a rolling new drug application (NDA) submission to the U.S. Food and Drug Administration (FDA) for vamorolone for the treatment of Duchenne muscular dystrophy (DMD). Vamorolone for DMD has been granted Fast Track Designation by the FDA. Santhera and ReveraGen have now commenced the NDA filing as a rolling submission following a successful pre-NDA meet

Advertisement
Advertisement